Applied Nanotools Inc

Applied Nanotools Inc. is an Edmonton-based company specializing in the production of high-quality X-Ray & EUV optics, calibration standards, gratings, and integrated photonics. Their state-of-the-art electron beam lithography system allows for the rapid prototyping of integrated photonic circuits. For X-Ray optics, Applied Nanotools offers optics with exceptional resolution, efficiency, and reliability at competitive prices, catering to a range of applications including ptychography, STXM, TXM, and phase contrast imaging. Their calibration standards are designed with nanoscale features, available for both soft and hard X-Ray regimes, EUV, and optical setups. The company also provides custom transmission gratings for EUV and higher energy X-ray systems, with the capability to fabricate high-resolution gratings ranging from several hundred micrometres to millimetres. Additionally, their integrated photonics fabrication service offers rapid prototyping and low-to-mid volume production, achieving feature sizes as small as 60 nm. Generated from the website content

Norcada Inc, based in Edmonton, Canada, is a leading company specializing in the development and manufacturing of MEMS devices and mid-IR DFB lasers for a diverse range of industrial and scientific applications. Established in 2002, Norcada operates a cutting-edge MEMS and photonics fabrication facility in Edmonton, situated within a prominent nanotechnology cluster in Canada. Offering a wide array of standard products and custom devices tailored to meet specific customer requirements, Norcada's product line includes silicon nitride TEM grids, membrane devices for X-ray microscopy, and MEMS chips for in-situ microscopy, among others. With a focus on innovation and expertise in MEMS design and fabrication, Norcada continues to provide high-quality solutions for scientific and industrial applications. Generated from their website

Fedora Pharmaceuticals Inc., founded in 2011 and headquartered in Edmonton, Alberta, is dedicated to addressing the global challenge of antimicrobial resistance (AMR) through the discovery and development of novel antimicrobial agents. The company has a robust pipeline of antibiotic candidates, with Nacubactam being its most advanced product, designed to inhibit beta-lactamases that compromise the effectiveness of many commonly prescribed antibiotics. With a management and scientific team rich in expertise in drug discovery and development, Fedora is committed to advancing innovative solutions to combat multidrug-resistant pathogens. The company aims to select one or more antibiotic candidates for clinical trials by 2022, contributing to the fight against antibiotic-resistant infections that pose a significant threat to global health. Generated from the website